A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Patients with Myelodysplastic Syndromes
|
Aug 2020
|
Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation
|
myelodysplastic syndromes (MDS)
|
Low participation rates and disparities in participation in interventional clinical trials for myelodysplastic syndromes
|
Aug 2020
|
Cancer
|
myelodysplastic syndromes (MDS)
|
Good but not good enough: Clinical trial participation of patients with myelodysplastic syndromes
|
Aug 2020
|
Cancer
|
myelodysplastic syndromes (MDS)
|
Mutations in myelodysplastic syndromes: Core abnormalities and CHIPping away at the edges
|
Aug 2020
|
International Journal of Laboratory Hematology
|
myelodysplastic syndromes (MDS)
|
Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes
|
Aug 2020
|
Nature Medicine
|
myelodysplastic syndromes (MDS)
|
Myelodysplastic Syndromes: 2021 update on Diagnosis, Risk-stratification and Management
|
Aug 2020
|
American Journal of Hematology
|
myelodysplastic syndromes (MDS)
|
High serum ferritin levels in newly diagnosed patients with myelodysplastic syndromes are associated with greater symptom severity
|
Aug 2020
|
International Journal of Hematology
|
myelodysplastic syndromes (MDS)
|
Safety and activity of selinexor in patients with myelodysplastic syndromes or oligoblastic acute myeloid leukaemia refractory to hypomethylating agents: a single-centre, single-arm, phase 2 trial
|
Aug 2020
|
Lancet Hematology
|
acute myeloid leukemia (AML), myelodysplastic syndromes (MDS)
|
Patients with paroxysmal nocturnal hemoglobinuria demonstrate a prothrombotic clotting phenotype which is improved by complement inhibition with eculizumab
|
Aug 2020
|
American Journal of Hematology
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype
|
Jul 2020
|
Blood
|
acute myeloid leukemia (AML), myelodysplastic syndromes (MDS)
|